Cargando…
Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
Over the years, many biological and synthetic agents have been explored and tested in attempts to halt the spread of cancer and/or cure it. Currently, several natural compounds have and are being considered in this regard. For example, paclitaxel is a potent anticancer drug that originates from the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203197/ https://www.ncbi.nlm.nih.gov/pubmed/37229270 http://dx.doi.org/10.3389/fphar.2023.1157306 |
_version_ | 1785045578376282112 |
---|---|
author | Sousa-Pimenta, Mário Estevinho, Letícia M. Szopa, Agnieszka Basit, Mahnoor Khan, Khushbukhat Armaghan, Muhammad Ibrayeva, Manshuk Sönmez Gürer, Eda Calina, Daniela Hano, Christophe Sharifi-Rad, Javad |
author_facet | Sousa-Pimenta, Mário Estevinho, Letícia M. Szopa, Agnieszka Basit, Mahnoor Khan, Khushbukhat Armaghan, Muhammad Ibrayeva, Manshuk Sönmez Gürer, Eda Calina, Daniela Hano, Christophe Sharifi-Rad, Javad |
author_sort | Sousa-Pimenta, Mário |
collection | PubMed |
description | Over the years, many biological and synthetic agents have been explored and tested in attempts to halt the spread of cancer and/or cure it. Currently, several natural compounds have and are being considered in this regard. For example, paclitaxel is a potent anticancer drug that originates from the tree Taxus brevifolia. Paclitaxel has several derivatives, namely, docetaxel and cabazitaxel. These agents work by disrupting microtubule assembling dynamics and inducing cell cycle arrest at the G2/M phase of the cell cycle, ultimately triggering apoptosis. Such features have helped to establish paclitaxel as an authoritative therapeutic compound against neoplastic disorders. After the completion of compound (hemi) synthesis, this drug received approval for the treatment of solid tumors either alone or in combination with other agents. In this review, we explore the mechanisms of action of paclitaxel and its derivatives, the different formulations available, as well as the molecular pathways of cancer resistance, potential risks, and other therapeutic applications. In addition, the role of paclitaxel in hematological malignancies is explored, and potential limitations in the therapeutic use of paclitaxel at the clinical level are examined. Furthermore, paclitaxel is known to cause increased antigen presentation. The immunomodulatory potential of taxanes, alone or in combination with other pharmacologic agents, is explored. Despite terpene-alkaloids derivatives’ anti-mitotic potential, the impact of this class of drugs on other oncogenic pathways, such as epithelial-to-mesenchymal transition and the epigenetic modulation of the transcription profile of cancer cells, is also analyzed, shedding light on potential future chemotherapeutic approaches to cancer. |
format | Online Article Text |
id | pubmed-10203197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102031972023-05-24 Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel Sousa-Pimenta, Mário Estevinho, Letícia M. Szopa, Agnieszka Basit, Mahnoor Khan, Khushbukhat Armaghan, Muhammad Ibrayeva, Manshuk Sönmez Gürer, Eda Calina, Daniela Hano, Christophe Sharifi-Rad, Javad Front Pharmacol Pharmacology Over the years, many biological and synthetic agents have been explored and tested in attempts to halt the spread of cancer and/or cure it. Currently, several natural compounds have and are being considered in this regard. For example, paclitaxel is a potent anticancer drug that originates from the tree Taxus brevifolia. Paclitaxel has several derivatives, namely, docetaxel and cabazitaxel. These agents work by disrupting microtubule assembling dynamics and inducing cell cycle arrest at the G2/M phase of the cell cycle, ultimately triggering apoptosis. Such features have helped to establish paclitaxel as an authoritative therapeutic compound against neoplastic disorders. After the completion of compound (hemi) synthesis, this drug received approval for the treatment of solid tumors either alone or in combination with other agents. In this review, we explore the mechanisms of action of paclitaxel and its derivatives, the different formulations available, as well as the molecular pathways of cancer resistance, potential risks, and other therapeutic applications. In addition, the role of paclitaxel in hematological malignancies is explored, and potential limitations in the therapeutic use of paclitaxel at the clinical level are examined. Furthermore, paclitaxel is known to cause increased antigen presentation. The immunomodulatory potential of taxanes, alone or in combination with other pharmacologic agents, is explored. Despite terpene-alkaloids derivatives’ anti-mitotic potential, the impact of this class of drugs on other oncogenic pathways, such as epithelial-to-mesenchymal transition and the epigenetic modulation of the transcription profile of cancer cells, is also analyzed, shedding light on potential future chemotherapeutic approaches to cancer. Frontiers Media S.A. 2023-05-09 /pmc/articles/PMC10203197/ /pubmed/37229270 http://dx.doi.org/10.3389/fphar.2023.1157306 Text en Copyright © 2023 Sousa-Pimenta, Estevinho, Szopa, Basit, Khan, Armaghan, Ibrayeva, Sönmez Gürer, Calina, Hano and Sharifi-Rad. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Sousa-Pimenta, Mário Estevinho, Letícia M. Szopa, Agnieszka Basit, Mahnoor Khan, Khushbukhat Armaghan, Muhammad Ibrayeva, Manshuk Sönmez Gürer, Eda Calina, Daniela Hano, Christophe Sharifi-Rad, Javad Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
title | Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
title_full | Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
title_fullStr | Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
title_full_unstemmed | Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
title_short | Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
title_sort | chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203197/ https://www.ncbi.nlm.nih.gov/pubmed/37229270 http://dx.doi.org/10.3389/fphar.2023.1157306 |
work_keys_str_mv | AT sousapimentamario chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT estevinholeticiam chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT szopaagnieszka chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT basitmahnoor chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT khankhushbukhat chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT armaghanmuhammad chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT ibrayevamanshuk chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT sonmezgurereda chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT calinadaniela chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT hanochristophe chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel AT sharifiradjavad chemotherapeuticpropertiesandsideeffectsassociatedwiththeclinicalpracticeofterpenealkaloidspaclitaxeldocetaxelandcabazitaxel |